What is ELITE PHARMS INC's earnings per share (EPS)?

ELITE PHARMS INC (ELTP) reported diluted earnings per share of $0.03 for fiscal year 2026. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

ELITE PHARMS INC (ELTP) Financials

ELTP

Trailing 12 months to June 30, 2026

Revenue $141.0M +33.7% YoY

Net Income $56.7M +624.0% YoY

EPS (Diluted) $0.04 +500.0% YoY

Free Cash Flow $17.5M -2.8% YoY

Market Cap $274.8M as of Oct 9, 2026

Price / Sales 1.9x on $141.0M revenue, trailing 12 months to June 30, 2026

Price / Earnings 4.8x on $56.7M net income, trailing 12 months to June 30, 2026

Price / Book 2.6x on $104.8M equity, Q1 FY2027

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 9, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2027, ended Jun 30, 2026 Reported Aug 13, 2026 Currency USD FYE March

Newest figures come from the 10-Q for Q1 FY2027, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ELTP SEC filings page.

ELITE PHARMS INC (ELTP) reported $141.0M in revenue over the twelve months to Jun 30, 2026, up 33.7% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ELTP FY2026 2026-10-03

Elite Pharmaceuticals has become a much larger, more profitable operation, while cash generation now broadly validates earnings.

Revenue reached $148.9M and operating margin reached 33.0% in FY2026, making scale accompanied by stronger operating efficiency the central change. The combination suggests more sales were converted into operating profit through better cost absorption, rather than growth coming from volume alone.

The balance sheet is less debt-dependent than the earnings expansion might suggest: FY2026 debt-to-equity was 0.4x and the current ratio was 6.4x. That structure gives the business substantial short-term asset coverage relative to its reported obligations.

FY2026 operating cash flow of $23.7M nearly matched free cash flow of $22.8M, so reinvestment consumed relatively little of the cash produced. This marks a cash-conversion reversal from the negative operating cash flow recorded in FY2024, indicating that reported profitability is now translating into cash rather than remaining mainly accounting-based.

Financial Health Signals

Financial health score not available

ELITE PHARMS INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Safe

6.49

ELITE PHARMS INC scores 6.49, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($274.8M) relative to total liabilities ($39.4M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

6/8

ELITE PHARMS INC passes 6 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Mixed

0.53x

For every $1 of reported earnings, ELITE PHARMS INC generates $0.53 in operating cash flow ($23.7M OCF vs $44.9M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Interest Coverage Safe

441.03x

ELITE PHARMS INC earns $441.03 in operating income for every $1 of interest expense ($49.1M vs $111K). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$32.4M

YoY-19.5%

QoQ-20.6%

5Y CAGR+35.6%

10Y CAGR+25.8%

ELITE PHARMS INC generated $32.4M in revenue in Q1 2027. This represents a decrease of 19.5% from the same quarter a year earlier. Against the prior quarter it is down 20.6%.

EBITDA

$7.8M

YoY-64.6%

QoQ-25.4%

5Y CAGR+43.5%

ELITE PHARMS INC's EBITDA was $7.8M in Q1 2027, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 64.6% from the same quarter a year earlier. Against the prior quarter it is down 25.4%.

Net Income

$5.9M

YoY+200.4%

QoQ-68.0%

5Y CAGR+19.9%

10Y CAGR+18.3%

ELITE PHARMS INC reported $5.9M in net income in Q1 2027. This represents an increase of 200.4% from the same quarter a year earlier. Against the prior quarter it is down 68.0%.

EPS (Diluted)

$0.01

YoY+200.0%

ELITE PHARMS INC earned $0.01 per diluted share (EPS) in Q1 2027. This represents an increase of 200.0% from the same quarter a year earlier.

Cash & Balance Sheet

Free Cash Flow

$9.3M

YoY-36.4%

QoQ+5.9%

ELITE PHARMS INC generated $9.3M in free cash flow in Q1 2027, representing cash available after capex. This represents a decrease of 36.4% from the same quarter a year earlier. Against the prior quarter it is up 5.9%.

Cash & Debt

$39.4M

YoY+77.6%

QoQ+30.2%

5Y CAGR+52.7%

10Y CAGR+11.9%

ELITE PHARMS INC held $39.4M in cash as of Q1 2027; long-term debt is not reported for that period.

Shares Outstanding

1.08B

YoY+0.6%

5Y CAGR+1.3%

10Y CAGR+3.9%

ELITE PHARMS INC had 1.08B shares outstanding in Q1 2027. This represents an increase of 0.6% from the same quarter a year earlier.

Dividends Per Share

Not reported for Q1 2027.

Margins & Returns

Gross Margin

41.8%

YoY-26.0pp

QoQ-9.2pp

5Y change-8.6pp

10Y change+7.4pp

ELITE PHARMS INC's gross margin was 41.8% in Q1 2027, indicating the percentage of revenue retained after direct costs. This is down 26.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 9.2 percentage points.

Operating Margin

23.3%

YoY-30.7pp

QoQ-1.7pp

5Y change+9.6pp

10Y change+61.1pp

ELITE PHARMS INC's operating margin was 23.3% in Q1 2027, reflecting core business profitability. This is down 30.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.7 percentage points.

Net Margin

18.3%

YoY+32.9pp

QoQ-27.0pp

5Y change-15.6pp

10Y change-15.3pp

ELITE PHARMS INC's net profit margin was 18.3% in Q1 2027, showing the share of revenue converted to profit. This is up 32.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 27.0 percentage points.

Return on Equity

5.6%

YoY+18.0pp

QoQ-13.0pp

5Y change-7.1pp

ELITE PHARMS INC's ROE was 5.6% in Q1 2027, measuring profit generated per dollar of shareholder equity. This is up 18.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 13.0 percentage points.

Capital Allocation

R&D Spending

$2.0M

YoY+21.3%

QoQ+23.8%

5Y CAGR+11.1%

ELITE PHARMS INC invested $2.0M in research and development in Q1 2027. This represents an increase of 21.3% from the same quarter a year earlier. Against the prior quarter it is up 23.8%.

Capital Expenditures

$809K

YoY+270.7%

QoQ+103.2%

ELITE PHARMS INC invested $809K in capex in Q1 2027, funding long-term assets and infrastructure. This represents an increase of 270.7% from the same quarter a year earlier. Against the prior quarter it is up 103.2%.

Share Buybacks

Not reported for Q1 2027.

ELTP Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ELTP quarterly income statement

Metric	TTM	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Revenue	$141.0M	$148.9M+77.1%	$84.0M+48.4%	$56.6M+65.8%	$34.2M+5.9%	$32.3M+27.1%	$25.4M+41.0%	$18.0M+137.8%	$7.6M+1.5%	$7.5M-22.6%	$9.6M-22.9%	$12.5M+149.2%	$5.0M+9.0%	$4.6M+35.2%	$3.4M+40.4%	$2.4M
Cost of Revenue	$79.7M	$73.8M+68.0%	$44.0M+45.2%	$30.3M+72.4%	$17.6M+0.5%	$17.5M+29.3%	$13.5M+34.9%	$10.0M+113.1%	$4.7M+33.9%	$3.5M-40.5%	$5.9M+31.5%	$4.5M+48.8%	$3.0M-6.9%	$3.2M+39.8%	$2.3M+128.4%	$1.0M
Gross Profit	$61.3M	$75.0M+87.2%	$40.1M+52.1%	$26.4M+58.8%	$16.6M+12.2%	$14.8M+24.7%	$11.9M+48.7%	$8.0M+178.2%	$2.9M-27.4%	$3.9M+5.6%	$3.7M-53.3%	$8.0M+300.4%	$2.0M+46.6%	$1.4M+25.4%	$1.1M-22.8%	$1.4M
R&D Expenses	$6.1M	$5.7M-27.9%	$8.0M+15.7%	$6.9M+11.0%	$6.2M+53.0%	$4.1M-20.8%	$5.1M-7.6%	$5.5M-27.2%	$7.6M-21.0%	$9.6M+15.9%	$8.3M-33.2%	$12.4M-15.6%	$14.7M+272.0%	$4.0M+306.0%	$975K-43.8%	$1.7M
SG&A Expenses	$17.7M	$17.6M+95.5%	$9.0M+26.0%	$7.1M+39.5%	$5.1M+14.7%	$4.5M+34.3%	$3.3M-0.8%	$3.3M+8.6%	$3.1M+32.2%	$2.3M+12.0%	$2.1M-28.2%	$2.9M0.0%	$2.9M+37.9%	$2.1M+39.1%	$1.5M+7.3%	$1.4M
Operating Income	$34.9M	$49.1M+150.6%	$19.6M+81.7%	$10.8M+193.5%	$3.7M-27.5%	$5.1M+140.9%	$2.1M+192.1%	-$2.3M+75.0%	-$9.2M-1.2%	-$9.1M-23.0%	-$7.4M+11.6%	-$8.3M+49.6%	-$16.5M-212.4%	-$5.3M-238.0%	-$1.6M+20.5%	-$2.0M
EBITDA	N/A	$50.2M+141.0%	$20.8M+72.0%	$12.1M+144.5%	$5.0M-21.1%	$6.3M+83.7%	$3.4M+454.0%	-$966K+87.8%	-$7.9M+1.9%	-$8.1M-21.3%	-$6.6M+13.2%	-$7.7M+52.0%	-$15.9M-229.7%	-$4.8M-323.8%	-$1.1M+23.1%	-$1.5M
Interest Expense	$110K	$111K-13.2%	$128K-78.2%	$589K-47.1%	$1.1M+480.1%	$192K-26.1%	$260K-27.1%	$356K-3.6%	$369K+10.0%	$335K+40.8%	$238K-15.1%	$281K-2.3%	$287K-66.6%	$859K+238.7%	$254K+10.5%	$230K
Income Tax	$8.4M	$11.9M+180.2%	$4.3M+121.7%	-$19.6M-4733.1%	$424K+124.4%	-$1.7M	N/A	N/A	-$676K+35.4%	-$1.0M+44.0%	-$1.9M-258.8%	-$520K-15918.8%	-$3K+98.9%	-$293K	N/A	N/A
Net Income	$56.7M	$44.9M+1140.0%	-$4.3M-121.5%	$20.1M+464.6%	$3.6M-60.0%	$8.9M+74.9%	$5.1M+327.1%	-$2.2M+75.9%	-$9.3M-152.6%	-$3.7M-196.4%	$3.8M+658.0%	-$683K-113.1%	$5.2M+112.7%	-$41.3M-2873.0%	$1.5M+109.9%	-$15.1M
EPS (Basic)	N/A	$0.04	$0.00-100.0%	$0.02	$0.00-100.0%	$0.010.0%	$0.01	$0.00+100.0%	-$0.01	$0.00-100.0%	$0.03+400.0%	-$0.01-120.0%	$0.05+123.8%	-$0.21	$0.00+100.0%	-$0.06
EPS (Diluted)	$0.04	$0.03	$0.00-100.0%	$0.02	$0.00-100.0%	$0.01	$0.00	$0.00+100.0%	-$0.01	-$0.010.0%	-$0.010.0%	-$0.01+50.0%	-$0.02+90.5%	-$0.21	$0.00+100.0%	-$0.06
Diluted Shares (Avg)	N/A	1.14B+6.6%	1.07B+4.4%	1.02B+1.0%	1.01B+0.2%	1.01B+7.2%	943M-5.1%	993M+21.7%	816M	798M-5.5%	845M+25.3%	674M-11.0%	758M+63.6%	463M-12.1%	527M+103.3%	259M

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Revenue	$32.4M-19.5%	$40.7M+27.4%	$31.6M+119.9%	$36.3M+92.4%	$40.2M+113.9%	$32.0M+78.3%	$14.4M-7.6%	$18.9M+33.4%
Cost of Revenue	$18.8M+45.1%	$20.0M+35.9%	$18.6M+126.0%	$22.2M+108.3%	$13.0M+25.7%	$14.7M+49.5%	$8.2M-3.0%	$10.7M+38.6%
Gross Profit	$13.5M-50.4%	$20.8M+20.1%	$13.0M+111.7%	$14.1M+71.7%	$27.2M+221.3%	$17.3M+113.0%	$6.1M-13.1%	$8.2M+27.1%
R&D Expenses	$2.0M+21.3%	$1.6M-19.6%	$1.0M-42.0%	$1.4M-29.5%	$1.7M-22.6%	$2.0M+18.8%	$1.8M+27.8%	$2.0M-24.9%
SG&A Expenses	$3.5M+4.3%	$7.7M+278.3%	$2.5M-9.5%	$4.0M+77.2%	$3.4M+72.9%	$2.0M-9.1%	$2.7M+59.2%	$2.3M+48.3%
Operating Income	$7.5M-65.3%	$10.2M-8.7%	$9.0M+721.0%	$8.2M+135.7%	$21.7M+461.6%	$11.2M+199.1%	$1.1M-68.9%	$3.5M+81.0%
EBITDA	$7.8M-64.6%	$10.4M-9.4%	$9.3M+557.9%	$8.5M+128.7%	$22.0M+424.9%	$11.5M+184.4%	$1.4M-63.6%	$3.7M+64.8%
Interest Expense	$27K-5.6%	$27K-7.8%	$27K-11.6%	$28K-14.8%	$29K-17.4%	$29K-86.6%	$31K-74.4%	$33K-74.6%
Income Tax	$1.8M-66.1%	$2.4M+5.2%	$2.2M+836.5%	$2.0M+31.0%	$5.3M+2193.5%	$2.3M+270.7%	$239K+129.9%	$1.5M+108.6%
Net Income	$5.9M+200.4%	$18.5M+8.6%	$18.6M+270.7%	$13.7M+224.2%	-$5.9M-1055.7%	$17.0M+411.1%	-$10.9M-1642.0%	-$11.0M-173.9%
EPS (Basic)	$0.01+200.0%	$0.020.0%	$0.02+300.0%	$0.01+200.0%	-$0.01	$0.02	-$0.01	-$0.01-200.0%
EPS (Diluted)	$0.01+200.0%	$0.01	$0.01	$0.01+200.0%	-$0.01	$0.02	-$0.01	-$0.01-200.0%
Diluted Shares (Avg)	1.13B+5.6%	N/A	1.14B	1.14B+6.9%	1.07B-0.7%	N/A	1.07B+4.3%	1.07B+4.8%

ELTP Balance Sheet

ELTP quarterly balance sheet

Metric	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Total Assets	$138.3M+43.5%	$96.4M+15.2%	$83.7M+104.6%	$40.9M+16.4%	$35.1M+34.2%	$26.2M+4.9%	$25.0M+2.3%	$24.4M-21.0%	$30.9M-10.0%	$34.3M+8.3%	$31.7M+22.2%	$25.9M+6.6%	$24.3M+118.6%	$11.1M+7.9%	$10.3M
Current Assets	$112.1M+94.2%	$57.7M+44.3%	$40.0M+86.0%	$21.5M+14.0%	$18.9M+54.7%	$12.2M+19.0%	$10.3M+15.7%	$8.9M-35.4%	$13.7M-25.6%	$18.4M+10.2%	$16.7M+35.5%	$12.3M+24.2%	$9.9M+290.2%	$2.5M+69.8%	$1.5M
Cash & Equivalents	$30.3M+157.2%	$11.8M+65.6%	$7.1M-9.3%	$7.8M-8.2%	$8.5M+167.3%	$3.2M+182.1%	$1.1M-50.3%	$2.3M-68.3%	$7.2M-32.2%	$10.6M-8.0%	$11.5M+54.2%	$7.5M+7.5%	$6.9M+1781.1%	$369K-44.8%	$668K
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$21.3M+30.9%	$16.2M+25.6%	$12.9M+35.4%	$9.6M+41.7%	$6.7M+34.5%	$5.0M+21.0%	$4.1M-8.3%	$4.5M-7.8%	$4.9M-23.7%	$6.4M+94.8%	$3.3M+8.6%	$3.0M+56.9%	$1.9M+42.3%	$1.4M+345.5%	$305K
Accounts Receivable	$59.7M+104.5%	$29.2M+50.1%	$19.5M+528.6%	$3.1M+1.2%	$3.1M-12.5%	$3.5M-14.9%	$4.1M+210.7%	$1.3M+95.6%	$676K-27.6%	$934K-39.0%	$1.5M+5.8%	$1.4M+97.6%	$732K+10.1%	$665K+67.6%	$397K
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$39.4M-8.1%	$42.9M+64.4%	$26.1M+118.4%	$11.9M+20.2%	$9.9M-1.1%	$10.0M-29.8%	$14.3M-46.9%	$26.9M+2.3%	$26.3M+204.3%	$8.6M-86.7%	$64.8M+6.8%	$60.7M-42.5%	$105.5M+432.9%	$19.8M-21.7%	$25.3M
Current Liabilities	$17.4M+46.9%	$11.8M-9.3%	$13.0M+66.6%	$7.8M+17.0%	$6.7M+15.2%	$5.8M-32.7%	$8.6M+25.1%	$6.9M+35.0%	$5.1M+52.9%	$3.3M-27.9%	$4.6M-8.5%	$5.1M-17.7%	$6.2M+15.0%	$5.4M+17.8%	$4.5M
Non-Current Liabilities	$22.0M-29.1%	$31.0M+138.3%	$13.0M+217.4%	$4.1M+26.9%	$3.2M-23.5%	$4.2M-25.4%	$5.7M-7.2%	$6.1M-16.4%	$7.3M+37.5%	$5.3M-66.6%	$15.9M-22.9%	$20.6M-79.3%	$99.4M+588.0%	$14.4M-30.4%	$20.7M
Long-Term Debt	N/A	N/A	N/A	N/A	$1.2M-15.3%	$1.5M-6.7%	$1.6M	N/A	N/A	N/A	N/A	N/A	$19K	N/A	N/A
Total Equity	$98.9M+84.8%	$53.5M-7.1%	$57.6M+98.8%	$29.0M+14.8%	$25.2M+56.2%	$16.2M+51.6%	$10.7M+524.9%	-$2.5M-154.9%	$4.6M-82.2%	$25.7M+177.5%	-$33.1M+4.6%	-$34.7M+57.2%	-$81.2M-836.2%	-$8.7M+42.1%	-$15.0M
Retained Earnings	-$75.8M+37.2%	-$120.7M-3.7%	-$116.4M+14.7%	-$136.5M+2.5%	-$140.1M+6.0%	-$149.0M+3.3%	-$154.0M-1.5%	-$151.8M-6.5%	-$142.5M-2.6%	-$138.9M+2.7%	-$142.7M-0.5%	-$142.0M+36.9%	-$225.0M-75.2%	-$128.4M+1.1%	-$129.9M

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Total Assets	$139.7M+25.4%	$138.3M+43.5%	$126.4M+39.3%	$117.2M+32.9%	$111.3M+26.7%	$96.4M+15.2%	$90.8M+21.5%	$88.2M+24.7%
Current Assets	$114.5M+47.0%	$112.1M+94.2%	$96.8M+101.4%	$85.8M+89.4%	$77.9M+80.4%	$57.7M+44.3%	$48.0M+29.3%	$45.3M+30.4%
Cash & Equivalents	$39.4M+77.6%	$30.3M+157.2%	$21.6M+146.6%	$27.1M+170.8%	$22.2M+150.9%	$11.8M+65.6%	$8.7M+50.3%	$10.0M+15.5%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$24.2M+25.0%	$21.3M+30.9%	$25.1M+24.5%	$18.2M+28.2%	$19.4M+39.9%	$16.2M+25.6%	$20.2M+40.7%	$14.2M-7.0%
Accounts Receivable	$50.4M+39.3%	$59.7M+104.5%	$48.5M+163.0%	$40.9M+90.6%	$36.2M+76.8%	$29.2M+50.1%	$18.5M+15.3%	$21.4M+104.3%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$34.8M-45.3%	$39.4M-8.1%	$46.1M-15.1%	$55.7M+36.0%	$63.7M+115.1%	$42.9M+64.4%	$54.3M+92.0%	$40.9M+59.7%
Current Liabilities	$30.4M+182.8%	$17.4M+46.9%	$13.2M-10.2%	$10.7M-17.0%	$10.8M-23.2%	$11.8M-9.3%	$14.7M-23.3%	$12.9M-32.6%
Non-Current Liabilities	$4.4M-91.7%	$22.0M-29.1%	$32.9M-16.9%	$45.0M+60.2%	$52.9M+239.5%	$31.0M+138.3%	$39.6M+334.3%	$28.1M+328.9%
Total Equity	$104.8M+119.8%	$98.9M+84.8%	$80.3M+120.4%	$61.6M+30.3%	$47.7M-18.1%	$53.5M-7.1%	$36.4M-21.5%	$47.3M+4.8%
Retained Earnings	-$69.9M+44.8%	-$75.8M+37.2%	-$94.3M+31.5%	-$112.9M+11.0%	-$126.6M-9.3%	-$120.7M-3.7%	-$137.7M-15.0%	-$126.8M-5.3%

Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.

ELTP Cash Flow Statement

ELTP quarterly cash flow statement

Metric	TTM	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Operating Cash Flow	$19.0M	$23.7M+218.5%	$7.5M+330.5%	-$3.2M-196.9%	$3.3M-48.7%	$6.5M+103.8%	$3.2M+278.0%	-$1.8M+73.6%	-$6.8M-41.2%	-$4.8M+39.0%	-$7.9M-185.1%	-$2.8M+81.7%	-$15.1M-258.2%	-$4.2M-117.0%	-$1.9M-393.1%	-$394K
Depreciation & Amortization	N/A	$1.1M-12.6%	$1.2M-7.1%	$1.3M+3.4%	$1.3M+5.7%	$1.2M-8.0%	$1.3M-0.5%	$1.3M+5.0%	$1.3M+26.1%	$996K+39.4%	$715K+7.2%	$666K+14.5%	$582K+28.2%	$454K+7.2%	$423K-12.6%	$484K
Stock-Based Compensation	N/A	$177K-22.4%	$228K+42.3%	$160K+306.7%	$39K+174.0%	$14K+8.9%	$13K-78.8%	$62K-54.5%	$136K-44.3%	$245K-31.6%	$358K+7.4%	$333K+28.2%	$260K-45.6%	$478K+227.3%	$146K-31.5%	$213K
Capital Expenditures	$1.5M	$926K-43.0%	$1.6M+100.7%	$810K-85.9%	$5.7M+1050.6%	$499K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	$17.5M	$22.8M+291.4%	$5.8M+244.2%	-$4.0M-68.7%	-$2.4M-139.9%	$6.0M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$1.5M	-$926K+61.4%	-$2.4M-196.4%	-$810K+85.9%	-$5.7M-1050.6%	-$499K-89.7%	-$263K-651.8%	-$35K-110.6%	$331K+220.4%	-$275K+75.1%	-$1.1M+43.3%	-$1.9M	N/A	N/A	-$192K+70.8%	-$658K
Financing Cash Flow	-$306K	-$4.3M-423.4%	-$826K-124.7%	$3.3M+96.2%	$1.7M+355.2%	-$667K+23.3%	-$870K-226.1%	$690K-56.0%	$1.6M-6.2%	$1.7M-79.3%	$8.1M-7.9%	$8.8M	N/A	N/A	$1.8M+1838.8%	-$106K

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Operating Cash Flow	$10.1M-31.8%	$9.1M+133.4%	-$5.3M-396.2%	$5.1M+250.4%	$14.8M+369.9%	$3.9M+86.6%	-$1.1M+55.5%	$1.5M+717.5%
Depreciation & Amortization	$253K-8.1%	$252K-13.2%	$269K-14.2%	$275K+21.1%	$275K-14.5%	$290K-11.6%	$313K-8.9%	$227K-30.5%
Stock-Based Compensation	$28K-45.6%	N/A	$45K-36.1%	$50K-4.6%	$52K0.0%	N/A	$71K+41.7%	$52K+22.3%
Capital Expenditures	$809K+270.7%	$398K-47.2%	$206K	$103K+11.8%	$218K-72.0%	$754K+86.8%	$0	$92K
Free Cash Flow	$9.3M-36.4%	$8.7M+176.5%	-$5.5M-415.6%	$5.0M+266.5%	$14.6M+515.3%	$3.2M+86.6%	-$1.1M	$1.4M
Investing Cash Flow	-$809K-270.7%	-$398K+47.2%	-$206K	-$103K-688.6%	-$218K+86.9%	-$754K-86.8%	$0	$18K
Financing Cash Flow	-$115K+97.2%	-$42K+69.7%	-$34K+82.6%	-$116K+63.7%	-$4.1M-2261.7%	-$137K+65.8%	-$193K-413.9%	-$321K-78.7%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

ELTP Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ELTP quarterly financial ratios

Metric	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Gross Margin	50.4%+2.7pp	47.7%+1.1pp	46.6%-2.0pp	48.6%+2.7pp	45.9%-0.9pp	46.8%+2.4pp	44.3%+6.5pp	37.9%-15.0pp	52.9%+14.1pp	38.8%-25.3pp	64.1%+24.2pp	39.9%+10.2pp	29.7%-2.3pp	32.0%-26.2pp	58.2%
Operating Margin	33.0%+9.7pp	23.3%+4.3pp	19.1%+8.3pp	10.8%-5.0pp	15.7%+7.4pp	8.3%+21.0pp	-12.7%	-121.0%	-121.4%	-76.3%-9.8pp	-66.5%	-329.1%	-114.8%	-45.9%+35.2pp	-81.1%
Net Margin	30.1%+35.3pp	-5.1%-40.6pp	35.5%+25.1pp	10.4%-17.1pp	27.6%+7.5pp	20.1%+32.5pp	-12.4%	-122.6%	-49.3%-88.8pp	39.5%+45.0pp	-5.5%	104.1%	-896.7%	43.7%	-621.2%
Return on Equity	45.4%+53.4pp	-8.1%-43.0pp	34.9%+22.6pp	12.3%-23.0pp	35.3%+3.8pp	31.5%+52.5pp	-21.0%	N/A	-80.3%-95.2pp	14.8%	N/A	N/A	N/A	N/A	N/A
Return on Assets	32.5%+36.9pp	-4.5%-28.5pp	24.0%+15.3pp	8.7%-16.6pp	25.3%+5.9pp	19.4%+28.4pp	-9.0%+29.1pp	-38.0%-26.1pp	-11.9%-23.0pp	11.1%+13.3pp	-2.2%-22.3pp	20.1%+189.8pp	-169.7%-183.0pp	13.4%+159.4pp	-146.0%
Current Ratio	6.45+1.6x	4.88+1.8x	3.07+0.3x	2.75-0.1x	2.82+0.7x	2.10+0.9x	1.19-0.1x	1.28-1.4x	2.68-2.8x	5.50+1.9x	3.60+1.2x	2.43+0.8x	1.61+1.1x	0.47+0.1x	0.33
Debt-to-Equity	0.40-0.4x	0.80+0.3x	0.450.0x	0.41+0.4x	0.050.0x	0.09-0.1x	0.15	N/A	5.76+5.4x	0.34	N/A	N/A	N/A	N/A	N/A
Asset Turnover	1.08+0.2x	0.87+0.2x	0.68-0.2x	0.84-0.1x	0.92-0.1x	0.97+0.2x	0.72+0.4x	0.31+0.1x	0.240.0x	0.28-0.1x	0.39+0.2x	0.190.0x	0.19-0.1x	0.31+0.1x	0.24
FCF Margin	15.3%+8.4pp	6.9%+14.1pp	-7.1%-0.1pp	-7.0%-25.7pp	18.6%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Gross Margin	41.8%-26.0pp	51.0%-3.1pp	41.0%-1.6pp	38.8%-4.7pp	67.7%+22.6pp	54.0%+8.8pp	42.6%-2.7pp	43.4%-2.1pp
Operating Margin	23.3%-30.7pp	25.0%-9.9pp	28.5%+20.9pp	22.6%+4.2pp	54.0%+33.4pp	34.9%+14.1pp	7.6%-15.1pp	18.5%+4.9pp
Net Margin	18.3%+32.9pp	45.3%-7.8pp	58.9%+134.7pp	37.7%+96.2pp	-14.6%-17.9pp	53.1%+34.6pp	-75.8%-80.4pp	-58.5%
Return on Equity	5.6%+18.0pp	18.7%-13.1pp	23.2%+53.0pp	22.3%+45.6pp	-12.3%-13.4pp	31.8%+26.0pp	-29.9%-31.4pp	-23.4%-56.5pp
Return on Assets	4.2%+9.5pp	13.4%-4.3pp	14.7%+26.7pp	11.7%+24.2pp	-5.3%-6.0pp	17.6%+13.7pp	-12.0%-13.0pp	-12.5%-33.6pp
Current Ratio	3.76-3.5x	6.45+1.6x	7.34+4.1x	8.04+4.5x	7.23+4.2x	4.88+1.8x	3.27+1.3x	3.52+1.7x
Debt-to-Equity	0.33-1.0x	0.40-0.4x	0.57-0.9x	0.900.0x	1.33+0.8x	0.80+0.3x	1.49+0.9x	0.87+0.3x
Asset Turnover	0.23-0.1x	0.290.0x	0.25+0.1x	0.31+0.1x	0.36+0.1x	0.33+0.1x	0.160.0x	0.210.0x
FCF Margin	28.6%-7.6pp	21.5%+11.6pp	-17.4%-10.0pp	13.8%+6.5pp	36.2%+23.6pp	9.9%+0.4pp	-7.4%	7.2%

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
ELITE PHARMS INC ELTP	FY2026	$148.9M	$44.9M	30.1%	$274.8M	—
NIKA PHARMACEUTICALS INC NIKA	FY2025	N/A	-$76K	N/A	$429.9M	—
GLASS HOUSE BRANDS INC GLASF	FY2025	$182.0M	-$29.7M	-16.3%	$1.0B	—
VERANO HLDGS CORP VRNOF	FY2025	$821.5M	-$258K	0.0%	$457.2M	—
CRESCO LABS INC CRLBF	FY2025	$655.8M	-$135.4M	-20.6%	$240.6M	—

Where ELITE PHARMS INC Ranks

Frequently Asked Questions

What is ELITE PHARMS INC's annual revenue?

ELITE PHARMS INC (ELTP) reported $148.9M in total revenue for fiscal year 2026. This represents a 77.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is ELITE PHARMS INC's revenue growing?

ELITE PHARMS INC (ELTP) revenue grew by 77.1% year-over-year, from $84.0M to $148.9M in fiscal year 2026.

Is ELITE PHARMS INC profitable?

Yes, ELITE PHARMS INC (ELTP) reported a net income of $44.9M in fiscal year 2026, with a net profit margin of 30.1%.

What is ELITE PHARMS INC's EBITDA?

ELITE PHARMS INC (ELTP) had EBITDA of $50.2M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.

What is ELITE PHARMS INC's gross margin?

ELITE PHARMS INC (ELTP) had a gross margin of 50.4% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.

What is ELITE PHARMS INC's operating margin?

ELITE PHARMS INC (ELTP) had an operating margin of 33.0% in fiscal year 2026, reflecting the profitability of core business operations before interest and taxes.

What is ELITE PHARMS INC's net profit margin?

ELITE PHARMS INC (ELTP) had a net profit margin of 30.1% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.

What is ELITE PHARMS INC's return on equity (ROE)?

ELITE PHARMS INC (ELTP) has a return on equity of 45.4% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.

What is ELITE PHARMS INC's free cash flow?

ELITE PHARMS INC (ELTP) generated $22.8M in free cash flow during fiscal year 2026. This represents a 291.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is ELITE PHARMS INC's operating cash flow?

ELITE PHARMS INC (ELTP) generated $23.7M in operating cash flow during fiscal year 2026, representing cash generated from core business activities.

What are ELITE PHARMS INC's total assets?

ELITE PHARMS INC (ELTP) had $138.3M in total assets as of fiscal year 2026, including both current and long-term assets.

What are ELITE PHARMS INC's capital expenditures?

ELITE PHARMS INC (ELTP) invested $926K in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.

How much does ELITE PHARMS INC spend on research and development?

ELITE PHARMS INC (ELTP) invested $5.7M in research and development during fiscal year 2026.

How many shares does ELITE PHARMS INC have outstanding?

ELITE PHARMS INC (ELTP) had 1.08B shares outstanding as of fiscal year 2026.

What is ELITE PHARMS INC's current ratio?

ELITE PHARMS INC (ELTP) had a current ratio of 6.45 as of fiscal year 2026, which is generally considered healthy.

What is ELITE PHARMS INC's debt-to-equity ratio?

ELITE PHARMS INC (ELTP) had a debt-to-equity ratio of 0.40 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is ELITE PHARMS INC's return on assets (ROA)?

ELITE PHARMS INC (ELTP) had a return on assets of 32.5% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.

What is ELITE PHARMS INC's P/E ratio?

ELITE PHARMS INC (ELTP) trades at 4.8x earnings, its market capitalization divided by net income of $56.7M net income, trailing 12 months to June 30, 2026. The market capitalization is $274.8M as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is ELITE PHARMS INC's price-to-sales ratio?

ELITE PHARMS INC (ELTP) trades at 1.9x sales, its market capitalization divided by revenue of $141.0M revenue, trailing 12 months to June 30, 2026. The market capitalization is $274.8M as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is ELITE PHARMS INC's Altman Z-Score?

ELITE PHARMS INC (ELTP) has an Altman Z-Score of 6.49, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is ELITE PHARMS INC's Piotroski F-Score?

ELITE PHARMS INC (ELTP) has a Piotroski F-Score of 6 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are ELITE PHARMS INC's earnings high quality?

ELITE PHARMS INC (ELTP) has an earnings quality ratio of 0.53x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can ELITE PHARMS INC cover its interest payments?

ELITE PHARMS INC (ELTP) has an interest coverage ratio of 441.03x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.